These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23357716)

  • 21. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
    J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toll-like receptor 4 suppression leads to islet allograft survival.
    Goldberg A; Parolini M; Chin BY; Czismadia E; Otterbein LE; Bach FH; Wang H
    FASEB J; 2007 Sep; 21(11):2840-8. PubMed ID: 17475921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppression With CD40 Costimulatory Blockade Plus Rapamycin for Simultaneous Islet-Kidney Transplantation in Nonhuman Primates.
    Oura T; Hotta K; Lei J; Markmann J; Rosales I; Dehnadi A; Kawai K; Ndishabandi D; Smith RN; Cosimi AB; Kawai T
    Am J Transplant; 2017 Mar; 17(3):646-656. PubMed ID: 27501203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of intra-islet endothelial cells in islet allo-immunity.
    Bharat A; Saini D; Benshoff N; Goodman J; Desai NM; Chapman WC; Mohanakumar T
    Transplantation; 2007 Nov; 84(10):1316-23. PubMed ID: 18049117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.
    Kim JS; Lee JI; Shin JY; Kim SY; Shin JS; Lim JH; Cho HS; Yoon IH; Kim KH; Kim SJ; Park CG
    Transplantation; 2009 Dec; 88(12):1349-59. PubMed ID: 20029331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study on the role of Th17 cells in the islet transplantation].
    Xiong JJ; Lu HM; Du XJ; Ke NW; Hu WM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 41(4):638-43. PubMed ID: 20848786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of gene transfer CTLA4Ig and anti-CD40L monoclonal antibody on islet xenograft rejection in mice.
    Zhang J; Li H; Jiang N; Zhang Q; Wang GS; Yi HM; Fu BS; Wang GY; Yang Y; Chen GH
    Transplant Proc; 2010 Jun; 42(5):1835-7. PubMed ID: 20620534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of graft-derived interleukin-15 in islet allograft rejection in mice.
    Lewis EC; Weiler M; Tejman-Yarden N; Ziv N; Mazar J; Chaimovitz C; Douvdevani A
    Cytokine; 2006 Apr; 34(1-2):106-13. PubMed ID: 16723256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells.
    Nasr IW; Wang Y; Gao G; Deng S; Diggs L; Rothstein DM; Tellides G; Lakkis FG; Dai Z
    J Immunol; 2005 May; 174(10):6161-8. PubMed ID: 15879112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH.
    Haeryfar SM; Lan Z; Leon-Ponte M; Duffy KR; Ge W; Liu W; Mele T; Garcia B; Wang H
    Transplantation; 2008 Aug; 86(3):460-8. PubMed ID: 18698251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
    Wang Y; Qin Q; Chen J; Kuang X; Xia J; Xie B; Wang F; Liang H; Qi Z
    Transpl Immunol; 2009 Dec; 22(1-2):5-11. PubMed ID: 19766187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of CD4+ and CD8+ cells in islet allo- and xeno-graft rejection.
    Gotoh M; Monden M; Yamamoto H; Kawai M; Ichikawa T; Mori T; Uenaka A; Nakayama E
    Horm Metab Res Suppl; 1990; 25():173-6. PubMed ID: 1982441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-2 knockout recipient mice reject islet cell allografts.
    Steiger J; Nickerson PW; Steurer W; Moscovitch-Lopatin M; Strom TB
    J Immunol; 1995 Jul; 155(1):489-98. PubMed ID: 7602120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct requirements for host CD80/CD86 costimulatory molecules in cardiac versus islet rejection.
    Johnson Z; Beilke J; Pietra B; Kelly B; Gill RG
    Transplant Proc; 2004 May; 36(4):1171-2. PubMed ID: 15194405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
    Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
    J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Islet allograft rejection is independent of toll-like receptor signaling in mice.
    Hutton MJ; Westwell-Roper C; Soukhatcheva G; Plesner A; Dutz JP; Verchere CB
    Transplantation; 2009 Nov; 88(9):1075-80. PubMed ID: 19898202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells.
    Nathan MJ; Yin D; Eichwald EJ; Bishop DK
    Am J Transplant; 2002 Apr; 2(4):323-32. PubMed ID: 12118853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection.
    Vergani A; Fotino C; D'Addio F; Tezza S; Podetta M; Gatti F; Chin M; Bassi R; Molano RD; Corradi D; Gatti R; Ferrero ME; Secchi A; Grassi F; Ricordi C; Sayegh MH; Maffi P; Pileggi A; Fiorina P
    Diabetes; 2013 May; 62(5):1665-75. PubMed ID: 23315496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medicinal herbs Fructus corni and Semen cuscutae suppress allograft rejection via distinct immune mechanisms.
    Liu X; Zeng YQ; Liang YZ; Zou C; Liu H; Qiu F; Liang CL; Jin XW; Su ZR; Dai Z
    Oncotarget; 2016 Jun; 7(24):35680-35691. PubMed ID: 27256977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients.
    Shariff H; Tanriver Y; Brown KL; Meader L; Greenlaw R; Mamode N; Jurcevic S
    Transplantation; 2010 Aug; 90(3):270-8. PubMed ID: 20571468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.